Background

Globally, ~500 000 people with severe dengue (SD) require hospitalization yearly; ~12 500 (2.5%) die. Secondary hemophagocytic lymphohistiocytosis (sHLH) is a potentially fatal hyperinflammatory condition for which HLH-directed therapy (as etoposide and dexamethasone) can be life-saving. Prompted by the high mortality in SD and the increasing awareness that patients with SD may develop sHLH, our objectives were to (1) determine the frequency of dengue-HLH in SD, (2) describe clinical features of dengue-HLH, (3) assess mortality rate in SD and dengue-HLH, and (4) identify mortality-associated risk factors in SD.

Methods

A 5-year retrospective single-center study in all adult patients with SD admitted to a tertiary intensive care unit in Malaysia.

Results

Thirty-nine of 180 (22%) patients with SD died. Twenty-one of 180 (12%) had HLH defined as an HLH probability ≥70% according to histo score (HScore); 9 (43%) died. Similarly, 12 of 31 (39%) fulfilling ≥4 and 7 of 9 (78%) fulfilling ≥5 HLH-2004 diagnostic criteria died. Peak values of aspartate aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase, and creatinine correlated to fatality (odds ratios [ORs], 2.9, 3.4, 5.8, and 31.9; all P < .0001), as did peak ferritin (OR, 2.5; P = .0028), nadir platelets (OR, 1.9; P = .00068), hepatomegaly (OR, 2.9; P = .012), and increasing age (OR, 1.2; P = .0043). Multivariable logistic regression revealed peak AST (OR, 2.8; P = .0019), peak creatinine (OR, 7.3; P = .0065), and SOFA (Sequential Organ Failure Assessment) score (OR, 1.4; P = .0051) as independent risk factors of death.

Conclusions

Be observant of dengue-HLH due to its high mortality. A prospective study is suggested on prompt HLH-directed therapy in SD patients with hyperinflammation and evolving multiorgan failure at risk of developing dengue-HLH.

1. Bhatt, S., Gething, P. W., Brady, O. J., et al. (2013). The global distribution and burden of dengue. Nature, 496, 504–507. https://doi.org/10.1038/nature12060

2. World Health Organization. (2019). WHO fact sheet: Dengue and severe dengue. https://www.who.int/en/news-room/fact-sheets/detail/dengue-and-severe-dengue

3. Janka, G. E. (2007). Familial and acquired hemophagocytic lymphohistiocytosis. European Journal of Pediatrics, 166, 95–109. https://doi.org/10.1007/s00431-006-0258-1

4. Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2014). Adult haemophagocytic syndrome. The Lancet, 383(9927), 1503–1516. https://doi.org/10.1016/S0140-6736(13)61048-X

5. Trottestam, H., Horne, A., Aricò, M., et al. (2011). Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118(17), 4577–4584. https://doi.org/10.1182/blood-2011-06-356261

6. Bergsten, E., Horne, A., Aricó, M., et al. (2017). Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-term results of the cooperative HLH-2004 study. Blood, 130(25), 2728–2738. https://doi.org/10.1182/blood-2017-06-788349

7. Imashuku, S., Hibi, S., Ohara, T., et al. (1999). Effective control of Epstein–Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood, 93(6), 1869–1874.

8. Imashuku, S., Kuriyama, K., Sakai, R., et al. (2003). Treatment of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: A report from the HLH study center. Medical and Pediatric Oncology, 41(2), 103–109. https://doi.org/10.1002/mpo.10341

9. Imashuku, S., Teramura, T., Tauchi, H., et al. (2004). Longitudinal follow-up of patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica, 89(2), 183–188.

10. Kogawa, K., Sato, H., Asano, T., et al. (2014). Prognostic factors of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group. Pediatric Blood & Cancer, 61(7), 1257–1262. https://doi.org/10.1002/pbc.24957

11. Wong, K. F., Chan, J. K., Chan, J. C., Lim, W. W., & Wong, W. K. (1991). Dengue virus infection-associated hemophagocytic syndrome. American Journal of Hematology, 38(4), 339–340. https://doi.org/10.1002/ajh.2830380420

12. Veerakul, G., Sanpakit, K., Tanphaichitr, V. S., Mahasandana, C., & Jirarattanasopa, N. (2002). Secondary hemophagocytic lymphohistiocytosis in children: An analysis of etiology and outcome. Journal of the Medical Association of Thailand, 85(Suppl. 2), S530–S541.

13. Tan, L. H., Lum, L. C., Omar, S. F., & Kan, F. K. (2012). Hemophagocytosis in dengue: Comprehensive report of six cases. Journal of Clinical Virology, 55(1), 79–82. https://doi.org/10.1016/j.jcv.2012.05.012

14. Raju, S., Kalyanaraman, S., Swaminathan, K., Nisha, A., & Praisid, S. (2014). Hemophagocytic lymphohistiocytosis syndrome in dengue hemorrhagic fever. Indian Journal of Pediatrics, 81(12), 1381–1383. https://doi.org/10.1007/s12098-014-1528-4

15. Pal, P., Giri, P. P., & Ramanan, A. V. (2014). Dengue associated hemophagocytic lymphohistiocytosis: A case series. Indian Pediatrics, 51(6), 496–497.

16. Wan Jamaludin, W. F., Periyasamy, P., Wan Mat, W. R., & Abdul Wahid, S. F. (2015). Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome. Journal of Clinical Virology, 69, 91–95. https://doi.org/10.1016/j.jcv.2015.05.011

17. Ellis, E. M., Sharp, T. M., Perez-Padilla, J., et al. (2016). Incidence and risk factors for developing dengue-associated hemophagocytic lymphohistiocytosis in Puerto Rico, 2008–2013. PLoS Neglected Tropical Diseases, 10(8), e0004939. https://doi.org/10.1371/journal.pntd.0004939

18. Jasmine, Y. S., Lee, S. L., & Kan, F. K. (2017). Infection associated haemophagocytic syndrome in severe dengue infection—a case series in a district hospital. Medical Journal of Malaysia, 72(1), 62–64.

19. Giang, H. T. N., Banno, K., Minh, L. H. N., et al. (2018). Dengue hemophagocytic syndrome: A systematic review and meta-analysis on epidemiology, clinical signs, outcomes, and risk factors. Reviews in Medical Virology, 28(6), e2005. https://doi.org/10.1002/rmv.2005

20. World Health Organization. (2009). Dengue: Guidelines for diagnosis, treatment, prevention and control. https://apps.who.int/iris/handle/10665/44188

21. Henter, J. I., Horne, A., Aricó, M., et al. (2007). HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 48(2), 124–131. https://doi.org/10.1002/pbc.21039

22. Fardet, L., Galicier, L., Lambotte, O., et al. (2014). Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis & Rheumatology, 66(9), 2613–2620. https://doi.org/10.1002/art.38690

23. Mia, M. S., Begum, R. A., Er, A. C., Abidin, R. D., & Pereira, J. J. (2013). Trends of dengue infections in Malaysia, 2000–2010. Asian Pacific Journal of Tropical Medicine, 6(6), 462–466. https://doi.org/10.1016/S1995-7645(13)60075-9

24. Malaysia Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia. (2015). Management of dengue infection in adults. http://www.moh.gov.my/moh/penerbitan/CPG/CPG%20Dengue%20Infection%20PDF%20Final.pdf

25. Afessa, B., Gajic, O., & Keegan, M. T. (2007). Severity of illness and organ failure assessment in adult intensive care units. Critical Care Clinics, 23(4), 639–658. https://doi.org/10.1016/j.ccc.2007.07.007

26. Minne, L., Abu-Hanna, A., & de Jonge, E. (2008). Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Critical Care, 12, R161. https://doi.org/10.1186/cc7160

27. Soundravally, R., Agieshkumar, B., Daisy, M., Sherin, J., & Cleetus, C. C. (2015). Ferritin levels predict severe dengue. Infection, 43(1), 13–19. https://doi.org/10.1007/s15010-014-0683-4

28. Grangé, S., Buchonnet, G., Besnier, E., et al. (2016). The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Critical Care Medicine, 44(11), e1045–e1053. https://doi.org/10.1097/CCM.0000000000001878

29. van de Weg, C. A., Huits, R. M., Pannuti, C. S., et al. (2014). Hyperferritinaemia in dengue virus infected patients is associated with immune activation and coagulation disturbances. PLoS Neglected Tropical Diseases, 8(10), e3214. https://doi.org/10.1371/journal.pntd.0003214

30. Tam, D. T., Ngoc, T. V., Tien, N. T., et al. (2012). Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: A randomized, placebo-controlled trial. Clinical Infectious Diseases, 55(9), 1216–1224. https://doi.org/10.1093/cid/cis655

31. Kawaguchi, H., Miyashita, T., Herbst, H., et al. (1993). Epstein–Barr virus-infected T lymphocytes in Epstein–Barr virus-associated hemophagocytic syndrome. The Journal of Clinical Investigation, 92(3), 1444–1450. https://doi.org/10.1172/JCI116731

32. Silveira, G. F., Wowk, P. F., Cataneo, A. H. D., et al. (2018). Human T lymphocytes are permissive for dengue virus replication. Journal of Virology, 92(3), e02181-17. https://doi.org/10.1128/JVI.02181-17

33. Buyse, S., Teixeira, L., Galicier, L., et al. (2010). Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Medicine, 36(10), 1695–1702. https://doi.org/10.1007/s00134-010-1936-z

34. Arca, M., Fardet, L., Galicier, L., et al. (2015). Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: Impact of triggering disease and early treatment with etoposide. British Journal of Haematology, 168(1), 63–68. https://doi.org/10.1111/bjh.13102

35. Ramachandran, B., Balasubramanian, S., Abhishek, N., Ravikumar, K. G., & Ramanan, A. V. (2011). Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India. Indian Pediatrics, 48(1), 31–35.

36. Joshi, R., Phatarpekar, A., Currimbhoy, Z., & Desai, M. (2011). Haemophagocytic lymphohistiocytosis: A case series from Mumbai. Annals of Tropical Paediatrics, 31(2), 135–140. https://doi.org/10.1179/1465328111Y.0000000018

37. Johnson, T. S., Terrell, C. E., Millen, S. H., Katz, J. D., Hildeman, D. A., & Jordan, M. B. (2014). Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. The Journal of Immunology, 192(1), 84–91. https://doi.org/10.4049/jimmunol.1302282

38. Ehl, S., Astigarraga, I., von Bahr Greenwood, T., et al. (2018). Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: Consensus statements by the HLH Steering Committee of the Histiocyte Society. The Journal of Allergy and Clinical Immunology: In Practice, 6(5), 1508–1517. https://doi.org/10.1016/j.jaip.2018.05.031